Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | POLK | Q9UBT6 | 1/20 | 0.47 |
| ▸ | POLH | Q9Y253 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.45 |
| ▸ | TUBB | P07437 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27793485 | 0.85 | KDM4E (0.50) | KDM4EPOLBHSD17B10USP2ALDH1A1 | |
| SCHEMBL205044 | 0.83 | KDM4E (0.50) | KDM4EPOLBHSD17B10USP2GAA | |
| SCHEMBL4847814 | 0.83 | KDM4E (0.53) | KDM4EPOLBHSD17B10ALDH1A1MEN1 | |
| SCHEMBL10497610 | 0.83 | CYP3A4 (0.53) | USP2GAAALDH1A1HTTCYP1A2 | |
| SCHEMBL21689951 | 0.82 | ALDH1A1 (0.51) | KDM4EPOLBALDH1A1HTTCYP1A2 | |
| SCHEMBL24379065 | 0.81 | GAA (0.54) | KDM4EPOLBHSD17B10USP2GAA | |
| SCHEMBL987157 | 0.81 | TUBB4A (0.45) | KDM4EPOLBUSP2HTTCYP1A2 | |
| SCHEMBL30745030 | 0.81 | HSD17B10 (0.51) | KDM4EPOLBHSD17B10USP2GAA | |
| SCHEMBL31347582 | 0.81 | GAA (0.50) | KDM4EPOLBHSD17B10USP2GAA | |
| SCHEMBL5240714 | 0.81 | HSD17B10 (0.51) | KDM4EPOLBHSD17B10USP2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2673285-B1 | KETOLIDE COMPOUNDS | WOCKHARDT LTD (IN) | 2017-07-19 | — | — | EP | claimed |
| US-20160083412-A1 | KETOLIDE COMPOUNDS | WOCKHARDT LIMITED (IN) | 2016-03-24 | — | — | US | claimed |
| US-20140005133-A1 | KETOLIDE COMPOUNDS | WOCKHARDT LIMITED (IN) | 2014-01-02 | — | — | US | claimed |
| EP-2673285-A1 | KETOLIDE COMPOUNDS | Wockhardt Limited (IN) | 2013-12-18 | — | — | EP | claimed |
| WO-2012076989-A1 | KETOLIDE COMPOUNDS | WOCKHARDT LIMITED (IN) | 2012-06-14 | — | — | WO | claimed |
| EP-3216798-A2 | KETOLIDE COMPOUNDS | Wockhardt Limited (IN) | 2017-09-13 | — | — | EP | disclosed |
| EP-2673285-B1 | KETOLIDE COMPOUNDS | WOCKHARDT LTD (IN) | 2017-07-19 | — | — | EP | disclosed |
| US-20160083412-A1 | KETOLIDE COMPOUNDS | WOCKHARDT LIMITED (IN) | 2016-03-24 | — | — | US | disclosed |
| US-9175031-B2 | Ketolide compounds | WOCKHARDT LIMITED (IN) | 2015-11-03 | — | — | US | disclosed |
| EP-2463283-B1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | PFIZER PROD INC (US) | 2014-06-11 | — | — | EP | disclosed |
| US-20140005133-A1 | KETOLIDE COMPOUNDS | WOCKHARDT LIMITED (IN) | 2014-01-02 | — | — | US | disclosed |
| US-8343944-B2 | Trisubstituted boron-containing molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| EP-2458995-A1 | TRISUBSTITUTED BORON-CONTAINING MOLECULES | Anacor Pharmaceuticals, Inc. (US) | 2012-06-06 | — | — | EP | disclosed |
| US-8119624-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110136763-A1 | TRISUBSTITUTED BORON-CONTAINING MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | PFIZER INC | 2011-02-17 | — | — | US | disclosed |
| US-7842713-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC (US) | 2010-11-30 | — | — | US | disclosed |
| EP-2010520-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | Pfizer Products Incorporated (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | GCK, GCKR, HK1 | KDM4E 1790/4885POLB 4200/4885HSD17B10 1912/4885 |
| US-20110136763-A1 | TRISUBSTITUTED BORON-CONTAINING MOLECULES | BCL6B, BCL6, BLK | KDM4E 2302/4885POLB 1638/4885HSD17B10 2288/4885 |
| US-20160083412-A1 | KETOLIDE COMPOUNDS | AKR1C3, AKR1D1, AKR1C1 | KDM4E 313/4885POLB 2635/4885HSD17B10 353/4885 |
| US-20140005133-A1 | KETOLIDE COMPOUNDS | AKR1C3, AKR1D1, AKR1C1 | KDM4E 298/4885POLB 2532/4885HSD17B10 325/4885 |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | GCK, GCKR, HK1 | KDM4E 1790/4885POLB 4200/4885HSD17B10 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.